Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno!
#ntidote
Protamine sulfate -mg for each mg of
eno!aparin by slo% I in/ection 0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued
therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued
th
therapy. &eparininduced thrombocytopenia occurs on ( day and may lead to
increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin
#ntidote
itamin 2 "#void "#void foods high in vitamin 2.
Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs:
Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institutehemoglobin, for Safe Medication Practicesand recommends completing a baseline hematocrit, serum creatinine, platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institutehemoglobin, for Safe Medication Practicesand recommends completing a baseline hematocrit, serum creatinine, platelet count coun t before starting patients on
anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued
therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline
information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin
#ntidote
itamin 2 "#void "#void foods high in vitamin 2.
Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin
#ntidote
itamin 2 "#void "#void foods high in vitamin 2.
Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on
&eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin
*no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy
No IM drugs during
Anticoagulants are antithrombotic drugs\ complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild
thrombocytopenia "#ppears on $ th day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy
No IM drugs during
Anticoagulants are antithrombotic drugs\ complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild
thrombocytopenia "#ppears on $ th day of therapy and resolves %ith continued
therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy.
The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy
No IM drugs during
Anticoagulants are antithrombotic drugs\ complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno!
#ntidote
Protamine sulfate -mg for each mg of
eno!aparin by slo% I in/ection 0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno!
#ntidote
Protamine sulfate -mg for each mg of
eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to
increased resist resistance ance to heparin therapy. sulfate sulfthe ate drug is antidote. ue to short half life overdose can be treated b yProtamine by %ithdra%ing )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to
increased resist resistance ance to heparin therapy. sulfate sulfthe ate drug is antidote. ue to short half life overdose can be treated b yProtamine by %ithdra%ing
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild
thrombocytopenia "#ppears on $ th day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno!
#ntidote
Protamine sulfate -mg for each mg of
eno!aparin by slo% I in/ection 0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug
)o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno!
#ntidote
Protamine sulfate -mg for each mg of
eno!aparin by slo% I in/ection 0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin
Anticoagulation therapy No IM drugs during Anticoagulants are antithrombotic drugs\
complete laboratory tests before the start of anticoagulant therapy to establish baseline information about the patient's coagulation status and to serve as a reference for comparison during therapy. The Institute for Safe Medication Practices recommends completing a baseline hematocrit, hemoglobin, serum creatinine, and platelet count coun t before starting patients on anticoagulant therapy
Types Ty pes of anticoagulant drugs: Unfractionated heparin oes not dissolve e!isting thrombus, but prevents the e!tension of the thrombus and more thrombi from forming. forming. May cause mild th thrombocytopenia "#ppears on $ day of therapy and resolves %ith continued therapy. &eparininduced thrombocytopenia occurs on (th day and may lead to
increased resistance resistance to heparin therapy. Protamine sulfate sulfate is antidote. ue to short half life overdose can be treated by b y %ithdra%ing the drug )o%molecular%eight heparin "*no!aparin, alteparin, and Tin+aparin *no!aparin ")oveno! #ntidote Protamine sulfate -mg for each mg of eno!aparin by slo% I in/ection
0arfarin "1oumadin #ntidote itamin 2 "#void "#void foods high in vitamin 2. Ta3es Ta3es 45 days to reach effective levels6 Usually begun b egun %hile patient still on &eparin